摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-哌啶-4-基-1H-苯并咪唑-5-腈 | 401568-55-6

中文名称
2-哌啶-4-基-1H-苯并咪唑-5-腈
中文别名
——
英文名称
2-piperidin-4-yl-1H-benzoimidazole-5-carbonitrile
英文别名
2-piperidin-4-yl-3H-benzimidazole-5-carbonitrile
2-哌啶-4-基-1H-苯并咪唑-5-腈化学式
CAS
401568-55-6
化学式
C13H14N4
mdl
——
分子量
226.281
InChiKey
KKPQFWUYRCNKQQ-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    516.9±40.0 °C(Predicted)
  • 密度:
    1.27±0.1 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    1.4
  • 重原子数:
    17
  • 可旋转键数:
    1
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.38
  • 拓扑面积:
    64.5
  • 氢给体数:
    2
  • 氢受体数:
    3

上下游信息

  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    2-哌啶-4-基-1H-苯并咪唑-5-腈(1,1'-bis(diphenylphosphino)ferrocene)palladium(II) dichloride potassium carbonate 作用下, 以 甲苯乙腈 为溶剂, 反应 22.0h, 生成 2-[1-(3-phenyl-pyrazin-2-yl)-piperidin-4-yl]-1H-benzoimidazole-5-carbonitrile
    参考文献:
    名称:
    [EN] NITROGEN- HETEROCYCLIC COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS
    [FR] COMPOSÉS AZOTÉS HÉTÉROCYCLIQUES CONVENANT COMME INHIBITEURS DE LA PHOSPHODIESTÉRASE 10
    摘要:
    芳基和杂环氮杂环化合物,以及含有它们的组合物,以及制备这类化合物的方法。本文还提供了通过抑制PDEIO治疗可治疗的疾病或疾病的方法,如肥胖症,非胰岛素依赖型糖尿病,精神分裂症,亨廷顿病,躁郁症,强迫症等。
    公开号:
    WO2011143129A1
  • 作为产物:
    描述:
    参考文献:
    名称:
    [EN] NITROGEN- HETEROCYCLIC COMPOUNDS AS PHOSPHODIESTERASE 10 INHIBITORS
    [FR] COMPOSÉS AZOTÉS HÉTÉROCYCLIQUES CONVENANT COMME INHIBITEURS DE LA PHOSPHODIESTÉRASE 10
    摘要:
    芳基和杂环氮杂环化合物,以及含有它们的组合物,以及制备这类化合物的方法。本文还提供了通过抑制PDEIO治疗可治疗的疾病或疾病的方法,如肥胖症,非胰岛素依赖型糖尿病,精神分裂症,亨廷顿病,躁郁症,强迫症等。
    公开号:
    WO2011143129A1
点击查看最新优质反应信息

文献信息

  • [EN] FUSED PYRIMIDINES AS AKT INHIBITORS<br/>[FR] PYRIMIDINES CONDENSÉES EN TANT QU'INHIBITEURS D'AKT
    申请人:BAYER SCHERING PHARMA AG
    公开号:WO2010091824A1
    公开(公告)日:2010-08-19
    The present invention relates to compounds of formula (I), a N-oxide or tautomer or stereoisomer thereof, or a salt thereof, wherein ring B and the imidazole to which it is fused, R4, R6, R7, R10, m and n have the meanings as given in the description and the claims, which are effective inhibitors of the Pi3K/Akt pathway, processes for their production and their use as pharmaceuticals.
    本发明涉及式(I)的化合物,其N-氧化物或互变异构体或立体异构体,或其盐,其中环B和与其融合的咪唑,R4、R6、R7、R10、m和n的含义如描述和权利要求中所给出,这些化合物是Pi3K/Akt途径的有效抑制剂,其生产过程及其作为药物的用途。
  • Synthesis and antimicrobial evaluation of substituted benzimidazolyl fluoroquinolones under conventional and microwave irradiation conditions
    作者:Batthini Guruswamy、Ramakrishnan Arul
    DOI:10.1515/hc-2012-0082
    日期:2012.10.1
    were prepared using a conventional methodology and with the help of a microwave irradiation technique. The structures of the synthesized compounds were established on the basis of spectral and analytical data. The antimicrobial activities of newly synthesized compounds were evaluated against a number of microorganisms by using ciprofloxacin as reference. Many of the evaluated compounds exhibit remarkable
    摘要 使用传统方法并借助微波辐射技术制备了新的环丙沙星类似物 3a-i。合成化合物的结构是根据光谱和分析数据确定的。通过使用环丙沙星作为参考,评估了新合成化合物对多种微生物的抗菌活性。许多被评估的化合物对革兰氏阳性菌如金黄色葡萄球菌、链球菌、芽孢杆菌、革兰氏阴性菌如大肠杆菌、肺炎克雷伯菌、铜绿假单胞菌、沙门氏菌、伤寒沙门氏菌和念珠菌具有显着的抗真菌活性。其中,化合物 3a、
  • Proline derivatives and use thereof as drugs
    申请人:Kitajima Hiroshi
    公开号:US20050245538A1
    公开(公告)日:2005-11-03
    The present invention aims at providing compounds having therapeutic effects due to a DPP-IV inhibitory action, and satisfactory as pharmaceutical products. The present inventors have found that derivatives having a substituent introduced into the γ-position of proline represented by the formula (I) wherein each symbol is as defined in the specification, have a potent DPP-IV inhibitory activity, and completed the present invention by increasing the stability.
    本发明旨在提供具有治疗效果的化合物,其作用是通过DPP-IV的抑制作用,并且作为药物产品具有令人满意的效果。本发明人发现,在丙氨酸的γ位上引入取代基的衍生物具有强效的DPP-IV抑制活性,并通过增加稳定性完成了本发明。
  • Proline derivatives and the use thereof as drugs
    申请人:——
    公开号:US20040106655A1
    公开(公告)日:2004-06-03
    The present invention aims at providing compounds having therapeutic effects due to a DPP-IV inhibitory action, and satisfactory as pharmaceutical products. The present inventors have found that derivatives having a substituent introduced into the &ggr;-position of proline represented by the formula (I) 1 wherein each symbol is as defined in the specification, have a potent DPP-IV inhibitory activity, and completed the present invention by increasing the stability.
    本发明旨在提供具有治疗作用的化合物,由于DPP-IV抑制作用而具有满意的药物产品。本发明人发现,具有引入取代基的脯氨酸γ-位置的衍生物,其化学式为(I)1,其中每个符号如规范中所定义,具有强效的DPP-IV抑制活性,并通过增加稳定性完成了本发明。
  • ARYL- AND HETEROARYL- NITROGEN-HETEROCYCLIC COMPOUNDS AS PDE10 INHIBITORS
    申请人:Allen Jennifer R.
    公开号:US20110306590A1
    公开(公告)日:2011-12-15
    Aryl- and heteroaryl-nitrogen heterocyclic compounds, and compositions containing them, and processes for preparing such compounds. Provided herein also are methods of treating disorders or diseases treatable by inhibition of PDE10, such as obesity, non-insulin dependent diabetes, schizophrenia, Huntington's Disease, bipolar disorder, obsessive-compulsive disorder, and the like.
    提供了芳基和杂芳基氮杂环化合物及含有它们的组合物,以及制备这些化合物的方法。本文还提供了治疗可通过抑制PDE10治疗的疾病或疾病的方法,例如肥胖症,非胰岛素依赖性糖尿病,精神分裂症,亨廷顿病,双相障碍,强迫症等。
查看更多